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Abstract
Chronic obstructive pulmonary disease is a serious health problem which places a significant eco-
nomic burden on health systems worldwide, due mostly to a significant number of acute exac-
erbation events. The prevention of these events is a common goal of COPD treatments, being
imperative that patient education and self-management programs are developed in order to arouse
patient’s awareness of their activity behavior and health condition.
Home telemonitoring has gained interest as a potential solution to the global challenge of
providing home care and encouraging patients to become more involved in the management of
their own health condition, and also as a way to bridge the gap between professional care and
patient self-management.
Making use of smartphone technology, the COPDHelper was developed, an application aimed
to improve the patient’s self-management of the pulmonary disease, assisting and guiding in the
diverse fields of pulmonary rehabilitation and treatment. Developed only for Android OS, in order
to be integrated in the Fraunhofer’s SmartCompanion, this telemonitoring system is composed
by two major modules: (1) Monitoring and (2) Counseling and Education. However, and since
self-awareness of the actual state of the disease is as much important as monitoring of the COPD
symptoms and patient’s vital signs, the focus of COPDHelper rests more precisely in detecting
and solving the small mistakes on the part of the patient when managing this pulmonary disease,
marking its main difference when compared with available methods.
By successfully adopting already implemented features of the SmartCompanion and making
use of external biomedical sensors, COPDHelper became an in-depth application, capable of cov-
ering the most relevant aspects of pulmonary disease self-management.
The evaluation of the developed system was performed via usability tests, to assess its effi-
ciency and coherence, and also user satisfaction when interacting with the system. The results
indicated that COPDHelper would be a successfully management tool for COPD patients, but
with some reservations regarding its use by senior patients. As commonly encountered in other
systems in its early stages of development, some COPDHelper features and components need
further improvements before this application is fit for routine use.
Keywords: Chronic Obstructive Pulmonary Disease. Self-management. Telemedicine
and telemonitoring. Android aplication. SmartCompanion
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Resumo
A doença pulmonar obstrutiva crónica representa, globalmente, um fardo económico significa-
tivo para os sistemas de saúdes, devido em grande parte ao número significativo de ocorrências
de exacerbações. A prevenção destas exacerbações é um dos principais objetivos do tratamento
da DPOC, sendo imperativa a criação e o desenvolvimento de programas capazes de educar e
consciencializar o paciente do seu atual estado da doença.
O conceito de telemonitorização tem ganho interesse como uma solução potencial para o de-
safio de prestação de cuidados domiciliários e de incentivo aos pacientes para estes se envolverem
mais ativamente na gestão da sua doença, e também como uma forma de colmatar a lacuna entre
os profissionais de saúde e a gestão que está a ser praticada pelo paciente.
Recorrendo a um smartphone, foi desenvolvido o COPDHelper, uma aplicação com o objec-
tivo de melhorar a gestão desta doença pulmonar, assistindo e aconselhando os pacientes nos mais
diversos campos dos programas de reabilitação pulmonar e tratamento da doença. Desenvolvido
apenas para sistema operativo Android, de modo a ser integrado num projeto desenvolvido pela
Fraunhofer, SmartCompanion, este sistema de telemonitorização é composto por dois módulos
principais: (1) monitorização e (2) aconselhamento e educação.
Contudo, e tendo em conta que a auto-consciencia do estado da doença por parte do paciente
é tão importante como a monitorização da progressão dos sintomas e dos sinais biomédicos do
paciente, o foco do COPDHelper incide de forma mais vincada na deteção e resolução de erros
praticados pelos pacientes aquando da gestão desta doença, destacando-se, desta forma, dos já
existentes sistemas de telemonitorização. Com a utilização de sensores biomédicos externos e da
integração de funcionalidades do SmartCompanion já implementadas, o COPDHelper torna-se
numa abrangente aplicação, capaz de cobrir os aspectos mais revelantes na gestão da DPOC.
A avaliação do sistema desenvolvido foi realizada via testes de usabilidade, de maneira a
avaliar não só a eficiência e coerência do sistema, mas também a satisfação do utilizador após uma
interação ativa com o sistema. Os resultados obtidos indicaram que o COPDHelper poderá vir a
ser uma ferramenta de gestão benéfica para os pacientes com DPOC, mas com algumas reservas
quanto à sua utilização por utilizadores séniores.
Como é comum em sistemas nas fases iniciais do desenvolvimento, algumas funcionalidade e
componentes do COPDHelper necessitarão ainda de melhoramentos futuros antes da sua incorpo-
ração em aplicações reais.
Keywords: Doença pulmonar obstructiva crónica. Auto-gestão. Telemedicina e telemon-
itorização. Aplicação Android. SmartCompanion
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Chapter 1
Introduction
"The lives of far too many people in the world are being blighted and cut short by chronic diseases
such as heart disease, stroke, cancer, chronic respiratory diseases and diabetes" - Lee Jong-wook,
former Director-General of World Health Organization (WHO).
Over the XXI century, the epidemiological burden of chronic diseases and their risk factors
have been increasing worldwide, especially in low and middle income countries [1]. Most coun-
tries, in special the ones where the increase of chronic disease has been remarkably noted, do not
have clear national policies for prevention and treatment of such diseases, having also to deal with
the practical realities of low resources [1].
In 2004, the projection of the number of deaths related to chronic disease was 35 million.
Figure 1.1 depicts such projections worldwide.
Figure 1.1: Estimated age standardized death rate caused by chronic diseases. Adapted from [2].
In 2012, the top ten was led mostly by chronic diseases, double the estimations for all infec-
tious diseases combined, (Figure 1.2). With this daunting death’s estimates, it is vitally important
that the impending chronic diseases pandemic is recognized, understood and acted on urgently.
[1]
The causes of the main chronic disease are well established and well known. Between the
most relevant risk factors are: unhealthy diet and excessive energy intake; physical inactivity; and
tobacco use. The high death rate in the low and middle income countries is mostly due to the
excessive tobacco consume.
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Figure 1.2: The top 10 leading causes of death worldwide. Adapted from [3].
From all listed death causes in Figure 1.2, chronic diseases present the most interesting chal-
lenge for telemonitoring, given that the long and continuous treatment needed for such diseases
becomes an advantage for such applications. Among the vast array of chronic diseases, there are
five which are gaining some relevance in the research field of telemonitoring: asthma, chronic
obstructive pulmonary disease (COPD), diabetes, coronary disease and congenital heart disease.
The scope of this master’s thesis will be directed towards the development of a monitoring system
to COPD, as will be further motivated in the next section.
1.1 Motivation
Chronic obstructive pulmonary disease is a serious health problem and a major cause of chronic
morbidity and mortality worldwide. According to World Health Organization estimates, COPD
was the fourth leading cause of death worldwide in 2004, accounting for 5.1% of all disease-
related deaths. The same study predicts an absolute increase of 3.5% in such numbers by 2030
[4]. In 2012 this disease was already the third leading cause of death worldwide, killing over 3
million people [5]. In the particular case of Portugal, according to the Fundação Portuguesa do
Pulmão, COPD was the fifth leading cause of death in 2006 [6]. Its prevalence was 5.3% in 2004,
increasing to 14.2% in 2009 [7, 8].
COPD places a significant economic burden on health systems worldwide, due mostly to a
significant number of hospital admissions and high frequency of urgency services [8, 9]. The
larger fraction of this total cost (58%) [10] is associated to COPD exacerbations, which are acute
events characterized by a significant worsening of lung function and symptoms, that lead to hos-
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pitalizations. The prevention of these events is a common goal of COPD treatment which goes
from smoking cessation, pharmacological therapy, education, and pulmonary rehabilitation to nu-
tritional interventions, vaccinations, oxygen therapy, and surgery [11].
The idea of using telemonitoring systems to help patients manage their disease in order to de-
crease the occurrence of exacerbations and prevent disease progression is an attractive alternative
to the most widely spread strategies. The potential to help patients acquire and practice the skills
they need to carry out disease-specific medical regimens and to guide changes in health behavior
[12], accounts for a strong motivation to the present work.
1.2 Objective
The main goal of this master’s thesis is the development of a monitoring system for COPD, capable
of advising the user in several topics regarding the management of the disease, warning both user
and healthcare specialist whenever some worrisome activity is detected, as well as monitoring the
vital signs and progression of the patient’s symptoms.
The rest of this master’s thesis is organized as follows: Chapter 2 presents an overview on
COPD and its clinical features, diagnosis and treatment as well as the current strategies to suc-
cessfully manage this pulmonary disease and prevent COPD exacerbations; Theoretical concepts
of telemonitoring and self-management and a literature review are presented in Chapter 3. Chap-
ter 4 details the tools and resources used to developed this monitoring system, as well as detailing
the functioning modules of the monitoring system itself. Chapter 5 details the system evaluation
results and a general discussion of the system’s limitations. Finally, in Chapter 6 is presented the
overall analysis of all the work done and of the possible future improvements.

Chapter 2
Chronic Obstructive Pulmonary Disease
2.1 Overview
Chronic obstructive pulmonary disease is a chronic disorder characterized by irreversible and pro-
gressive airflow limitation that causes severe physiologic and functional impairment in patients
with advanced disease [13]. Of all the major diseases, COPD is the only with continued increases
in prevalence and mortality rates, and it is estimated that the global burden of COPD will increase
substantially in the coming decades [14]. However, this disease is markedly underdiagnosed and
frequently undermanaged, as patients often attribute COPD symptoms to aging or cigarette smok-
ing. Is is also difficult to differentiate between this disease and asthma, do to the overlap in
pathophysiology, clinical presentation, pulmonary function test results, and treatment [13].
As the increasing global burden is associated with a great number of COPD exacerbations,
which are acute events characterized by a significant worsening of lung function and symptoms
[11], understanding their pathogenesis and determining their optimal treatment is an important
part of the overall management of this pulmonary disease [14].
2.1.1 Pathology
The pathologic changes in COPD are complex and occur in different locations: central conducting
airways, peripheral airways, lung parenchyma, and pulmonary vasculature [15]. The most patho-
logic lesion associated with COPD is inflammation, initiated by exposure to particles or gases.
Changes in the central airways can lead to chronic hypersecretion of mucus, produced by the
mucus glands in the larger airways.
The smaller bronchi and bronchioles (Figure 2.1), less than 2mm in diameter, are the major
site of airflow obstruction in COPD. An inflammation on these small airways is one of the earliest
changes to occur in the development of this pulmonary condition [15].
Pulmonary emphysema (Figure 2.2) is a pathologic change in the lung parenchyma character-
ized by an abnormal permanent enlargement of airspaces distal to the terminal bronchioles, as a
result of destruction of alveolar walls [15].
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Figure 2.1: Respiratory passageways: Tracheobronchial tree. Adapted from [16].
Pulmonary vascular changes are characterized by a thickening of the vessel walls. Thicken-
ing of the intima, followed by an increase in smooth muscle and infiltration of the vessel wall
with inflammatory cells, are changes that occur early in the course of COPD. Greater amounts of
smooth muscle, collagen, and proteoglycans present in the arterial wall will lead to its thickening
as COPD progresses [15].
Figure 2.2: Pathological change in the alveolar walls induced by emphysema. Adapted from [15].
2.1.2 Risk factors
A series of host factors and environmental exposures are considered to be risk factors of COPD,
as the disease arises from the interaction between these factors [17].
Smoking habit is considered to be the most important risk factor in COPD, as cigarette smokers
have more respiratory symptoms, lung function abnormalities, and a greater death rate from COPD
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than non-smokers [18]. However, not all smokers show deterioration in lung function and develop
clinically significant COPD, which may suggest that other risk factors, such as genetic factors,
must modify each individual’s risk [17]. Passive smoking may also contribute to chronic airflow
limitations, but its effect is not yet powerful enough to demonstrate clinical significance [15]. Still
concerning cigarette smoking, maternal smoking poses as a risk factor by affecting lung growth
and increasing the frequency of respiratory illness in the first years of life [17].
High levels of air pollution have been also recognized as a risk factor in COPD, as a result
of various air pollution episodes, such as the London smog of 1952 in which 4000 excess deaths
due to cardiorespiratory disease occurred. However, the role of air pollution in the development
of COPD seems to be small when compared with cigarette smoking [15].
Occupational exposure to dust or chemicals is associated with an increased risk of develop-
ing COPD by an increase in airway hyperresponsiveness [17]. Airway hyperresponsiveness is
also identified as a risk factor to the development of COPD but its way of influence is unknown.
This disorder is related to a number of genetic and environmental factors and may be a result of
smoking-related airway disease [17].
Concerning genetic factors, a variety of genes have been associated with the development
of this pulmonary condition, but the only proven association is with a rare hereditary deficiency
of alpha1-antitrypsin [17]. Studies have shown that premature and accelerated development of
panlobular emphysema and decline of lung function occur in patients with the severe deficiency
[19, 20].
The prevalence of COPD is, also, often associated with both low socioeconomic status, as well
as clinical history of respiratory infections in childhood [17].
2.2 Clinical features
Most patients with COPD seek for clinical attention late in the course of their disease. They
typically present a combination of signs and symptoms of chronic bronchitis, emphysema, and
reactive airway disease [15].
Breathlessness is a characteristically persistent and progressive symptom that often drives pa-
tients to seek for medical help and is usually a sign for the existence of moderate impairment of
expiratory flow. Changes in environmental temperature and exposure to dust or gases can trigger
severe breathlessness, with a sense of increased effort to breathe, heaviness, air hunger or gasping
[15].
Persistent or intermittent chronic cough is the most frequent symptom reported by COPD
patients. However, most patients frequently neglect it as a clinical sign. It may initially be inter-
mittent, but later extends throughout the day and throughout the year with sputum production. In
75% of the patients, cough either precedes the onset of breathlessness or appears simultaneously
with it [21].
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Sputum production often appears after coughing bouts, but its evaluation is rather difficult
because patients may swallow sputum instead of expectorate it. The presence of purulent sputum
reflects an increase in inflammatory mediators [21].
Regarding severe chest pain, it is not a feature of COPD, and its manifestation suggests com-
plication or other conditions that frequently coexist with COPD [21]. The sense of chest tightness
is usually complaint during worsening of breathlessness, particularly during exercise, and its cause
may be due to an overinflation of the lung [15].
In a severe stage of the disease, fatigue, weight loss, and anorexia are common symptoms,
thought to result from both decreased calorie intake and hypermetabolism. Depression is also
manifested in the severe stage of COPD [22].
2.3 Diagnosis and Assessment
2.3.1 Diagnosis
A clinical diagnosis of COPD should be considered to patients with symptoms of cough, sputum
production, or dyspnea, and/or history of exposure to risk factors for the disease.
In the early stages of the disease, physical examination may be inconclusive, as physical signs
are not usually present until significant impairment of lung function has occurred. Such signs
are also non-specific and depend on the degree of airflow limitation and pulmonary overinflation
[15]. As a diagnosis method for COPD, physical examination has relatively low sensibility and
specificity [17].
Pulmonary function tests play a key role in COPD, as not only help in the diagnosis, but also
assess the severity of the disease and evaluate the response to therapy. Spirometry is the most
robust and objective measurement of airflow limitation available [23], and although it measures
only a small aspect of COPD effects in patient’s health, it remains the gold standard for diagnosis
due to its availability and high reproducibility [17]. This method assesses the degree of airflow
limitation by measuring the force expiratory volume in 1 second (FEV1)1 and the ratio of FEV1
to forced vital capacity (FEV1/FVC) [10]. Forced vital capacity corresponds to the total exhaled
breath and, like FEV1, is measured in liters. In people with normal lung function, FEV1 is at least
70% of FVC whereas for patients with COPD presents low FEV1 with an FEV1/FVC ratio below
the normal range (normal range determined based on age, height, sex and race) [15].
To patients with FEV1 value below than 40% of the predicted or clinical signs of respiratory
failure or right heart failure, a complementary diagnosis method to assess arterial blood gases is
generally performed. This measurement will assist in the decision of whether or not the patient
needs ventilatory support [17].
The assessment of the reversibility of airflow limitations to bronchodilators has also been an
important test to differentiate between COPD and asthma, as higher postbronchodilator FEV1
value ( > 1.2%) is usually evidence of the presence of asthma. As for COPD patients, the spiro-
1FEV1 measures how much air a person can exhale during a forced breath at the first second
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metric test is characterized by a decreased FEV1 and FEV1/FVC ratio after the inhalation of a
bronchodilator, as illustrated in Figure 2.3. However, bronchodilator reversibility can vary be-
tween patients, change over time and differ according to the used bronchodilator [15].
Figure 2.3: Spirogram contrasting postbroncodilator FVC in patient with COPD and normal FVC.
Adapted from [22].
The diagnosis of COPD disease by imaging techniques is not performed, as this pulmonary
disease does not produce any specific features on plain chest radiograph [15]. Nevertheless, imag-
ing techniques can support the diagnosis and help exclude other conditions that produce similar
signs and symptoms. Most of the information collected in chest radiography on COPD relates
to pulmonary emphysema. Also, computer tomography scanning has been used to assist in the
COPD diagnosis, by detecting and quantifying emphysema [21]. Measurement of diffusing ca-
pacity can provide information on the functional impact of emphysema in COPD and may be
helpful in patients with breathlessness that may seen out of proportion with the degree of airflow
limitation [23].
2.3.2 Assessment of the Disease
The assessment of COPD is intended to determine (1) the severity of airflow limitation, (2) the
impact of the disease on the patient’s health status, and (3) the risk of future events, such as
exacerbations and hospital admissions. These three goals are accomplished by taking into con-
sideration some aspects of the disease separately: severity of airflow limitation, current level of
patient’s symptoms, exacerbation risk and the presence of comorbidities [24].
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According to the GOLD classification system, there are four categories for airflow limitation
severity, based on the degree of airflow limitation after the administration of an adequate dose of
short-acting inhaled bronchodilator (Table 2.1) [22].
Table 2.1: GOLD classification of airflow limitation severity. Adapted from [15].
Stage Characteristics
I: mild FEV1 > 80% predicted
II: moderate 50% < FEV1 < 80% predicted
III: severe 30% < FEV1 < 50% predicted
IV: very severe
FEV1 < 30% predicted or 30% <FEV1 < 50% predicted*
*with respiratory failure or clinical signs of right heart failure
The worsening of airflow limitation is associated with an increasing prevalence of exacerba-
tions and risk of death. For that being, this classification should be used as an indication to manage
COPD and guide therapy, in order to reduce and prevent the development of this chronic disease
[17, 24].
Measurements of the current level of patient’s symptoms and the impact of the disease in
their quality of life have proved to be of important value in addition to the assessment of airflow
limitation severity, as the latter has limitations with respect to symptoms and some aspects of
lung function. One of the most reported symptoms, dyspnea, can be measured during exercise
tests, where a modified Borg scale (Table 2.2) or a visual analogue scale are used to rate it [23].
There are also several validated questionnaires to assess patient’s symptoms, being the GOLD pri-
mary recommendations the Modified British Medical Research Council (mMRC), more focused
on breathlessness, and the COPD Assessment Test (CAT), which assesses not only the severity of
patient’s symptoms but also the impact that COPD has on the patient’s daily activities and well
being [23, 24]. Other questionnaires, such as Chronic Respiratory Disease Index Questionnaire
and the St. George’s Respiratory Questionnaire, are too complex to use in routine practice and
time-consuming, discouraging patients to complete them [15, 21].
Table 2.2: Modified Borg scale for the assessment of dyspnea. Adapted from [15].
Scale Severity experiment by Patient
0 Nothing at all
0.5 Very, very slight (just noticeable)
1 Very slight
2 Slight (light)
3 Moderate
4 Somewhat severe
5 Severe (heavy)
6
7 Very severe
8
9 Very, very severe (almost maximal)
10 Maximal
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The history of hospitalizations and treated events is the best predictor of the occurrence of
frequent exacerbations (two or more per year) and risk detector of possible future exacerbations
and hospital admissions. The severity of exacerbations can be classified in three stages: mild if a
change on the inhaled treatment is required; moderate when medical intervention including short
course of antibiotic/oral steroids is needed; and severe when the patient has to be hospitalized [24].
As a way of combining the aforementioned analysis of the different aspects of this pulmonary
disease and improve its management, GOLD developed the Combined COPD Assessment, where
patients are clustered into four different groups (A to D), depending on the triangulation of the
different assessments results.
Figure 2.4: Combined COPD Assessment. Adapted from [23].
Figure 2.4 depicts the combined COPD assessment’s table. By using the aforementioned
questionnaires (CAT or mMRC), it is determined if the patient belongs to the left or right side
of the table, depending on the final score of the questionnaires. To assess if the patient belongs to
the lower part (low risk) or the upper part of the table (high risk), the healthcare specialist can resort
to either spirometry, and assess the risk by the patient’s airflow severity, or, alternatively, assess
such risk by the number of exacerbation events that occurred within the previous 12 months [24].
In some patients, these two methods can lead to two different levels of risk. In this case, the risk
should be determined by the method indicating a higher level, preventing possible complications
in the patient’s treatment [24]. Hereupon, the healthcare specialist can properly direct the most
effective treatment and care to the patient. This combined assessment presents marked advantages
over the unidirectional analysis of airflow limitation, allowing a more in depth representation of
12 Chronic Obstructive Pulmonary Disease
the COPD complexity. Such capability makes this combined assessment a viable starting point to
achieve an individualized management of this pulmonary disease [24].
2.4 Management of COPD
An effective management of COPD consists, initially, on the early and accurate diagnosis, and
secondarily on the prevention and pharmacological treatment to reduce the impact of the disease
on patients [15]. As COPD is usually a progressive disease, where patient’s lung function can be
expected to worsen over time, it is necessary to perform an ongoing monitoring of the disease to
assess its severity and determine when to adjust therapy. This monitoring extends from oxygen
saturation, FEV1 value, and arterial blood gases measures to the evaluation of the health-related
quality of life, by means of questionnaires. Also, educational advice on health living should be
transmitted to COPD patients [17].
2.4.1 Reduction of risk factors
Smoking cessation is the most effective way to reduce the risk of developing COPD and stop its
progression [17]. The first Lung Health Study showed that stopping smoking was associated with
a reduced decline in FEV1 [25]. Specific resources to support COPD patients to quit smoking
should be an integral part of their care. Practical counseling and social support are part of an
effective smoking cessation intervention process but may not always be successful [17]. Numerous
effective pharmacotherapies have been developed to help patients quit smoking when counseling
is not sufficient. Nicotine replacement therapy in any form (nicotine gum, inhaler, nasal spray,
transdermal patch or sublingual tablet) reliably increases long-term smoking abstinence rates [17].
Reducing the risk of indoor and outdoor air pollution is feasible and requires a combination of
public policy, local and national resources, cultural changes, and protective changes taken by
individual patients. Also, reduction of exposure to dust or gases is crucial to reduce the prevalence
of COPD [17].
2.4.2 Reduction of symptoms and complications
Inhaled bronchodilators are currently considered the most effective pharmacologic therapy, as they
provide symptomatic relief and improve exercise capacity [15]. They are prescribed either on an
as-needed basic for relief of persistent or worsening of symptoms, or on a regular basis to pre-
vent and reduce symptoms. There are different classes of bronchodilators and the choice of which
to use depends on the patient’s response, and its availability and effectiveness in achieving the
desired outcome [15]. All categories of bronchodilators have been shown to increase exercise ca-
pacity without necessarily producing significant changes in FEV1. This therapy has, however, the
disadvantage of having significant cost implications. Corticosteroid drugs are the most commonly
prescribed anti-inflammatory agents, in order to reduce pulmonary inflammation. To patients in a
more severe stage of the disease, inhaled corticosteroids are prescribed with the view to prevent ex-
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acerbations. Nonetheless, patient education is required in furtherance of successfully conducting
this therapy, which is not always provided to the patients [26]. The intake of oral corticosteroids
increases FEV1 in approximately 10% on patients with symptomatic COPD [21]. However, in
patients in an advanced stage of the disease, the regular oral corticosteroids produce significant
side effects, like steroid myopathy, that contributes to muscle weakness, decreased functionality,
and respiratory failure. Also, there is no evidence of long-term benefits from this therapy [17].
Vaccines containing killed or live, inactivated viruses are a recommended treatment that should be
administered once or twice a year (autumn and winter) [17].
As a non-pharmacological treatment, pulmonary rehabilitation is an effective therapeutic pro-
gram that provides benefits over and above those that can be achieved with medications alone [15].
This therapeutic program aims towards the reduction of symptoms, improvement of the quality of
life, and to optimize physical and social performance. To achieve these goals, pulmonary rehabili-
tation covers a wide range of nonpulmonary problems, including exercise deconditioning, relative
social isolation, depression, muscle wasting, and weight loss. The two key principles that guide
the application of this program are that it should be tailored to meet the needs of each patient, and
several therapeutic components should be included [21]. One of them is the initial assessment and
goal setting to determine the actual health status, and enhance patient motivation and participation
in the program. Education is another program component, that should be undertaken with the goal
of improving patient adherence with the most effective health-enhancing behaviors. Correct use
of the medication and breathing exercises are some of the teaching given in the pulmonary reha-
bilitation program [15]. Exercise training is the most important component. Training programs
include both extremity aerobic training and upper extremity strengthening exercises, and should
follow the principles of exercise duration, session frequency, and exercise intensity. The benefits
of this training are an increase of the maximal oxygen uptake and exercise tolerance. After the
formal program, patients are encouraged to keep a balanced diet and to exercise three or four times
a week, in order to maintain the gains in performance and reduce the risk of hospital readmissions
[15].
Oxygen therapy is also provided to COPD patients in order to improve survival and reduce
breathlessness, and allow more exercise by eliminating exercise-induced hypoxemia [15]. It can
be administered in three forms with different purposes, depending on the arterial oxygen partial
pressure (PaO2) levels. Long-term continuous domiciliary oxygen therapy is provided in order to
raise the PaO2 to prevent mortality; ambulatory domiciliary oxygen therapy is provided to increase
exercise endurance and reduce dyspnea; and short-burst oxygen therapy is provided in healthcare
facilities for relief of breathlessness and improve the degree of pulmonary hypertension[15]. Usu-
ally patients do not fully understand the role of oxygen therapy. One of the most common mis-
understandings arises from the misconception that oxygen is only usable for dyspnea treatments,
and that, consequently, high doses of oxygen eliminate dyspnea. Therefore, patient education is a
prerequisite for proper use and adherence to oxygen therapy [15].
Another available treatment is lung volume reduction surgery that involves the removal of
areas of relatively poorly perfused but well-ventilated lungs. The resulting changes of this proce-
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dure should translate into less dyspnea during daily activities, and improved exercise capacity and
health status [15]. Notwithstanding these benefits, this surgery presents a high associated mortal-
ity rate and should only be suggested to patients who have significant dyspnea despite maximal
medical therapy [15].
2.4.3 Management of exacerbations
COPD is often associated with acute exacerbations of symptoms that occur more frequently with
increasing severity of the disease. Exacerbations of this pulmonary disease are a major cause of
morbidity and mortality, and lead to frequent hospital admissions and readmissions. They highly
contribute to the cost of managing patients who have COPD. Several factors can precipitate exac-
erbations, such as respiratory tract infections, air pollution, and the interruption of the maintenance
therapy. Influenza and pneumococcal vaccinations are recommended for all patients with COPD
in order to prevent the respiratory tract infections and, consequently, diminish the occurrence of
acute exacerbations. The pneumococcal vaccine is indicated to patients older than 65 years or
below 65 years with FEV1 < 40% [15]. Exacerbations most frequently present with increasing
sputum production, an increase in the purulence and viscosity of the sputum, increasing cough, and
worsening of dyspnea. Their diagnosis relies on the clinical presentation of the patient complain-
ing of an acute change of symptoms that is beyond the normal daily variations. The measurement
of arterial blood gases is essential to assess the severity of an exacerbation. When the PaO2 is
below 8.0 kPa, it is an indication of respiratory failure. In addition, PaO2 < 6.7 kPa, PaCO2 > 9.3
kPa, and pH > 7.3 indicate a life-threatening episode that needs close monitoring or intensive care
unit management [17].
When respiratory impairment is observed in the absence of a history of COPD, and if the
patient does not have clinical evidence of pneumonia, chest radiographs are useful in identifying
alternative conditions that mimic the symptoms of an exacerbation [15].
Treatment of COPD exacerbations depends on the severeness of the symptoms and ranges
from pharmacological therapy to ventilatory support. In the presence of mild symptoms, suit-
able for community management, the patient’s bronchodilator administration technique should be
checked and the dosage increased as appropriate. If the symptoms encompass increased dysp-
nea and increased sputum volume, antibiotic therapy and ventilatory support should be provided.
Also, oral or intravenous corticosteroids should be administered in short courses. In the presence
of severe symptoms that require hospital management, low flow oxygen therapy, bronchodilator
therapy every 4− 6 hours, ventilatory therapy (in case of pH < 7.3 and rising PaCO2) should be
provided to the patient in order to manage the exacerbations [15].
Most exacerbations of COPD are treated in a short period of time and have no long-term
sequelae. Increased patient education is necessary about detecting and tracking exacerbations,
and how to proper take the prescribed medication and maintain an active lifestyle [15]. Therefore,
in daily care facilities, healthcare professionals advice their patients to plan their days and weeks
carefully, in order to use their energy efficiently, spreading tasks and alternating between light and
heavy activities over the day [27].
Chapter 3
Telemonitoring and Self-Management
3.1 Overview
Acute exacerbations of COPD have a profound effect on the patient’s quality of life and prognosis.
The economic burden of exacerbations is extremely high, being imperative a patient education and
self-management programs to reduce the economic burden of the disease and improve the quality
of life. The ability to understand the activity behavior, the relationship with daily symptoms, and
the willingness of the patients to change is important for the success of any treatment. [28].
Self-management programs were developed to help patients acquire and practice skills they
need to carry out specific medical regimens. As patients’ awareness of their activity behavior is
the prerequisite for an effective treatment and management of the disease, the self-management
programs also have the goal to guide changes in health behavior and to provide emotional support
[28]. These programs are part of a pulmonary rehabilitation program that should be provided
not only to COPD patients but also to all patients with chronic illness. Schulman-Green et al.
[29], presented self-management as ongoing and dynamic, having overlapping processes (tasks
and skills), which consist in three categories: focusing on illness needs, activating resources and
living with a chronic illness.
Typically, outcome measures of self-management are encompassed in the following types:
Clinical/physiological (lung function and disease severity), functional (pain, exacerbations), cog-
nitive (physiological health, sell-efficacy), healthcare resource use (hospitalizations, emergency
appointments), healthcare cost, and behavior outcomes (exercise, diet) [12]. Barlow et al., Warsi
et al. and Rijken et al. [30, 31, 32], when assessing the effectiveness of self-management pro-
grams, reported that, generally, programs reveal positive results on some of the aforementioned
outcome measures, but rarely on all of them.
A Cochrane Collaboration review on 27 studies comparing self-management versus usual care
showed that self-management interventions are associated with improved quality of life, and re-
duced hospital admissions and readmissions [28]. It also concluded that self management without
exercise and self-management with exercise are equally effective in improving the health-related
quality of life of the COPD patients.
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Alongside pulmonary rehabilitation programs provided by healthcare facilities, the number
of patients with COPD being managed at home is increasing to reduce health-related costs while
increasing the patient’s comfort and health status [33]. Home telemonitoring is a relatively new
approach in the field of telemedicine, defined as the use of telecommunication technologies to
transmit data on patient’s health status from home to a healthcare center, and it is increasingly
seen as a way to bridge the gap between professional care and patient self-management [33]. A
first feasibility analysis of home-based services to prevent hospitalizations of COPD exacerbations
was reported in 1998 by Gravil et al. [34]. Over 3− 5 years, COPD patients were daily visited
by a respiratory nurse who monitored the progress of the disease with spirometry and oxygen
saturation. She also monitored adherence to the recommended treatment and offered reassurance,
support, and education [34]. The nurses collaborated with the respiratory medical staff to arrange
hospital admission if the patient deteriorated or failed to improve after completion of treatment
[34]. Gravil et al. [34] concluded that from the total of patients treated at home, only 12% required
admission during follow-up because of deteriorating of the disease and development of other com-
plications. Three subsequent controlled trials [35, 36, 37], performed in 2000, have demonstrated
both safety and cost reduction to the healthcare facilities when these types of services are applied
to COPD patients. In all of these trials, patients were followed by respiratory nurses every two
days at home, who monitored their health condition and the progression of the disease. Notwith-
standing the benefits that home telemonitoring has over the reduction of hospital admissions costs,
this service is highly dependent on nursing support, being necessary a countermeasure when this
support is scarce [34].
By systematically monitoring the health status of COPD patients, home telemonitoring can be
used for a timely assessment of an acute exacerbation or as a mechanism to generate alarms when
clinical changes that may constitute a risk to the patient occur [33]. This proactive monitoring has
a valuable advantage over its reactive counterpart, as the delayed seeking for treatment increases
recovery time and, consequently, lowers health-related quality of life [38]. In recent years, many
authors have tried to assess the importance and effectiveness of telemonitoring services for COPD
patients, without routine home visits by respiratory nurses. Technological devices, such as mobile
phones and personal computers, have been playing a leading role in the telemonitoring field, as
they store and transmit clinical data and, in the case of irregular values, they alert the clinicians
[39]. The landscape of these technological devices and wireless telemonitoring for disease man-
agement is extremely complex and rapidly evolving. However, some limitations are pointed out
by some authors as limiting factors of the aforementioned approaches. Despite of reducing the
hospital admissions and exacerbation treatment cost, the technology itself is expensive [40] and
elder patients have shown difficulties in the management of these new technologies, and in viewing
the information provided on screen [41]. Table 3.1 summarizes some of the most relevant studies
for COPD telemonitoring methodologies discussed in the Bartoli et al. and Cruz et al. reviews
[33, 39]. In all of these studies, patients were monitored and relevant clinical data was recorded,
such as oxygen saturation, pulse rate, FEV1, and level of dyspnea, through portable sensors and
medical devices (spirometer, oximeter). The recorded data was transmitted wirelessly to a central
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server, and subsequently monitored by a nurse or another healthcare professional [33, 39].
Table 3.1: Summary of the main characteristics of the studies.
Author Year Participants Duration Main Conclusions
De Toledo [42] 2006 157 1 year Improved heath status
Casas [43] 2006 158 2 years Reduced exacerbations hospitalizations
Paré [40] 2006 29 6 months Reduced exacerbations hospitalizations
Antoniades [44] 2012 44 1 year No significant difference in health status
Chau [41] 2012 53 2 months No significant difference in health status
Dale [45] 2003 55 3 months Decreased in rates of hospital readmissions
Kim [46, 47] 2012 144 6 months Positive results in patient satisfaction
Koff [48] 2009 40 3 months Improved quality of life
Lewis [49, 50] 2011 40 6 months No significant difference in health status
Sicotte [51] 2011 46 5 months Positive results in patient empowerment
Sund [52] 2009 20 6 months Decreased hospitalizations
Trappenburg [5] 2008 165 6 months Decreased hospitalizations
It is easily observable from Table 3.1 that all studies present a highly heterogeneous distri-
bution with regard to both number of participants, as well as results regarding the effectiveness
of telemonitoring applications/services. Such variability limits the possibility of an objective di-
rect comparison between studies. However, some interesting observations can still be performed
regarding individual conclusions from each singular study. Most patients reported that the tele-
monitoring system improved self-management of their health condition, as they had a better un-
derstanding of their disease, symptoms and ways to control them, were more involved in their
health care, and recognized earlier the signs of exacerbations [33]. However, high dropouts were
found in some studies [5, 41, 44, 46, 47, 52], as patients were not comfortable about using this
technology to monitor their health condition or had difficulties on using the technology in a correct
way. The authors concluded that patients should receive training over a period of several days to
help them learn how to use the technology and, therefore, optimize its use and reduce the number
of dropouts. Notwithstanding the disparities of experimental conditions regarding the technologi-
cal device used, the quality and reliability of data acquired during the survey were similar to those
obtained by clinical staff. It can, thus, be concluded that telemonitoring presents a great potential
to improve the outcomes in COPD patients and the feedback made possible by the numerous stud-
ies and reviews on the different existing methodologies can be a valuable input when developing
a new methodology. This technology should be: easy to use, operate without interruptions, and
provide security and confidentiality of data collected [33].
3.2 Related Work
In recent years, telemonitoring and self-management have been thoroughly explored to help in the
provision of feedback of symptoms and educational content, so that the health-related quality of
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life may be increased and the chronic condition controlled. From the available literature on the
topic a few works can be highlighted.
In order to allow a proper contextualization for the work developed in this master’s thesis, the
product SmartCompanion, where such project will be integrated, will be outlined in the following
section.
3.2.1 SmartCompanion
Fraunhofer Portugal Research Center for Assistive Information and Communication Solutions
(Fraunhofer AICOS), is the first research center operated by Fraunhofer Portugal, focused on en-
hancing the people’s living standards, by offering them intuitive and useful technological solutions
[53]. One of these solutions is the SmartCompanion, a customized android platform-based foun-
dation for other applications, appropriate to help and support the users in their daily activities
[53]. Also referred as a Swiss Army Knife, the SmartCompanion includes features designed to
promote the autonomy and quality of life, by giving access to relevant information, to improve
health management, by enabling monitoring or cognitive stimulation, and to prevent isolation, by
providing better communication tools, adapted for a senior user [53]. This product also enables
the user’s caretaker to receive alerts upon detected irregularities in the monitoring of the user [53].
The application developed in this Master’s Thesis will reinforce the sector of health management,
helping the user to keep its chronic disease under control (described in further detail on Chapter
4).
3.2.2 eCAALYX
Another project involving Fraunhofer AICOS is the eCAALYX project - Enhanced Complete
Ambient Assisted Living Experiment -, aimed to monitor user’s health status and improve the
quality of life [54, 55]. This is achieved by recording their vital signs over a longitudinal pe-
riod of time, to detect changes in their condition and, subsequently, in COPD progression. In
addition, and to improve the patient’s quality of life, this project proposes focused education on
their lifestyle and self-management [54]. The eCAALYX system uses two individual methods of
monitoring: a wearable body sensor system alongside a home-based system comprising multiple
sensors integrated into the user’s environmental [54]. The first method includes a smart garment
with embedded health and mobility sensors for respiratory rate, skin temperature, and heart rate,
controlled by an electronic control unit and connected via Bluetooth to a mobile phone, in order
to display the monitored data. The latter method encompasses a set top-box connected to a TV
that allows the visualization of the recorded vital signs and their historical recorded data. Fur-
thermore, an intelligent sensor system, which integrates the most relevant sensors for monitoring
chronic conditions, and a router are also incorporated (Figure 3.1). Such system is responsible
for receiving and processing all the measurements, as well as generating alarms on detection of a
health problem, and sending all monitored data to a caretaker site. [54].
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Figure 3.1: Global schematics of eCAALYX project. Adapted from [55].
3.2.3 Chronic Care Management Center
A chronic care telemedicine system, located at CCMC - Chronic Care Management Center -,
was designed to integrate a one year experience to determine the impact of telemedicine systems
on home care of chronic patients suffering from COPD. This system consists of a telemedicine
server and several user terminals that provide access to the services available, as well as a network
interconnecting all the elements [42]. The telemedicine center is composed by a call center, an
application server and an education material server. The call center uses computer-telephony
integration technology to, based on the service’s needs, delegate the phone calls to a member of
the care team or to direct the call to an automated voice response unit [42]. The patient’s records
are allocated in the application server, which can be accessed by all the members of the care team
from any location. Among the recorded data, the care team can consult the home-monitoring
reports, the schedule of medical appointments, the patient’s work plan and log of phone calls to
the call center. At last, the educational material server provides education on the disease to both
patients and professionals, either through web pages or using video-on-demand technology [42].
A disadvantage of this system is the required education sessions to patients and professionals, in
order for them to benefit more effectively from it.
3.2.4 AMICA
Based on innovative information and communication technologies and current chronic guidelines,
AMICA - Autonomy, Motivation & Individual Self Management for COPD Patients -, is a recent
telemedical solution that supports early detection of COPD exacerbations [56]. AMICA com-
bines a technical solution with a holistic service approach for disease management, encouraging
risk prevention and self-management through immediate, comprehensive feedback and efficient
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case management services [56]. This system provides two coexisting services. To healthcare
professionals it provides an ubiquitous access to an electronic patient record, which includes de-
mographic information, respiratory disorder history, therapy, exams, medical scale, and remote
monitoring data. To COPD patients it provides a remote monitoring of biomedical parameters,
such as ECG, pulse oximetry, lung sound, and symptoms; access to educational material and
social-motivation tools through dedicated mobile device; and report of problems to patients by
use of different media (Figure 3.2). The monitored data is transmitted via wireless to the patient
record for further analysis by a clinician and respective feedback [56].
Figure 3.2: Global schematics of AMICA telemedical platform. Adapted from [56].
3.2.5 ASTRI
The ASTRI telecare system [41] was developed to provide healthcare to COPD patients through
a combination of a modern broadband communications infrastructure and database, and software
for critical decision analysis and support (Figure 3.3a). It comprises a device kit, which includes
a designed mobile phone, a respiratory rate sensor and a pulse oximeter, a network platform, a
call center, and a networking system [41]. All the monitoring data acquired by the set of devices
is displayed on the mobile phone and sent to the platform and network server in which the data
is monitored and recorded. The device kit was also designed to send medication and purse-lip
breathing reminders. In the same way as AMICA [56], ASTRI does not provide autonomous
feedback. All the monitored data is analyzed a posteriori by a nurse, who can take the necessary
actions to address the patients’ needs [56].
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Figure 3.3: Schematic representation of the ASTRI and M-COPD projects. (a) ASTRI telecare
system, adapted from [41]; (b) M-COPD home care model, adapted from [57].
3.2.6 M-COPD
M-COPD [57], a mobile technology assisted home care model, was developed to enhance the link
between patients and clinicians (Figure 3.3b). It enables clinicians to remotely monitor COPD
patients conditions, diagnose exacerbations in the early stages, and treat mild or moderate exacer-
bations with prescribed medications at home [57]. The core functionality of the system is related
to the use of a mobile phone by the patient to update self-assessment and observation data relating
to COPD symptoms and vital signs, such as sputum, cough, wheezing, among others. The updated
data is stored in a remote server, being subsequently available to clinicians on a web portal [57].
With the transmitted information, clinicians are able to assess the patient health condition and dis-
ease progression, and take the necessary actions to prevent or treat the exacerbations. Also, patient
education regarding the correct form to administrate the medication is given through mobile video
calls [57].
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3.2.7 CHRONIOUS
The CHRONIOUS platform [58] is a partially automated system based on multi-parametric sen-
sor data processing and fusion to monitor people affected with chronic diseases (Figure 3.4). The
system consists of multiple unobstructive wearable sensors (Figure 3.4a), which monitor the elec-
trocardiographic and respiratory activity, arterial oxygen saturation, and skin temperature. The
aforementioned data is acquired and processed by different microprocessors integrated within a
data collector device. This device has the ability to analyze in real-time the collected data and,
according to decision tree-based algorithms, trigger special events. All the monitored data is
transmitted via Bluetooth to a PDA (Figure 3.4b), capable of directly issuing an alert to a clinician
when a problem is detected [58]. In addition to the wearable sensors, the CHRONIOUS system
also utilizes numerous wireless sensors placed within the home environment, recording data on
carbon monoxide levels, volatile organic compounds, and air particles. All of the monitored data
is also transmitted to a Central System (Figure 3.4b), capable of supplying clinical suggestions,
by integrating the interpretation of collected patient’s data and the clinical knowledge suitably
formalized [58].
3.2.8 VitalmobileTM Health
The VitalmobileTM Health company developed a wireless monitoring system capable of monitor-
ing the condition of the patient’s airways [59]. Using a series of biomedical sensors, continuously
monitoring the patient’s vital signs and transmitting the acquired data via Bluetooth to a smart-
phone and then to a secure database center, this system allows the processing and storage of the
raw data collected for future analysis (Figure 3.5). The analysis of this data by a specialist can
provide meaningful determinations of disease severity and predict future respiratory events [59].
3.2.9 EDGE
The EDGE - Self management and Support Programme - was developed in order to evaluate the
efficacy of a telemonitoring application and, subsequently, improve the user’s quality of life [60].
This program consists of a symptom diary and monitoring of pulse oximetry in regular periods
of time. Multimedia and self-management materials, such as videos, text and images were also
incorporated in this program. A tablet computer encompassed all the aforementioned components,
as patients were asked to complete the symptom diary, and the pulse oximetry values measured by
an external sensor [60].
3.2.10 Projects under development
The It’s Life! [62] is an innovative monitoring and feedback tool, still under development, aiming
to support the self-management of people with chronic diseases to obtain an active lifestyle. This
can be accomplished by measuring their activity behavior, and, subsequently, giving automatically
generated tailored feedback to the patient and to the clinician [62]. It consists in a 3D accelerom-
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(a)
(b)
Figure 3.4: CHRONIOUS platform components: (a) wearable sensors; (b) monitoring data anal-
ysis services. Adapted from [58].
eter connected via Bluetooth to a mobile phone that gives direct feedback to the user concerning
the amount of performed activity. The collected data can be also consulted in a secure web page
by both user and clinicians [62].
Another autonomous system [61] is currently under development (AERIAL ), aiming to pro-
vide computer aided self-management assistance and education, while also enabling the detection
of an ongoing exacerbation (Figure 3.6). The system consists of a mobile phone as the main com-
ponent, taking care of communication and computation [61]. Pulse oximeter and spirometer are
used to obtain valuable information about the patient’s health status, transmitted wirelessly to the
mobile phone. Another component of this system is a web-center, which receives the data from
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Figure 3.5: Vitalmobile Health monitoring service. Adapted from [59].
the mobile phone and provides data access for health-care workers [61]. The monitored data is
analyzed by means of a disease-specific probabilistic model that incorporates clinical variables
considered relevant by a clinical specialist. Subsequently to this analysis, feedback is given to the
patients regarding their current health status. This system also provides a questionnaire to assess
the development and stage of the patient’s symptoms [61].
3.2.11 Complements to COPD monitoring systems
3.2.11.1 TELEMOND
A Portuguese project, named TELEMOLD [63], was conducted with the objective of improving
long-term oxygen therapy, by monitoring oximetry and physical activity of chronic pulmonary
failure patients. These two parameters were monitored and recorded through the use of a portable
oximeter sensor and accelerometer, connected via Bluetooth to a mobile phone. This data is
then transmitted via 3G or radio service to a server, where healthcare professionals can analyze
the monitored data and adjust the oxygen prescription to a more adequate therapy [63]. This
project was not directly related to telemonitoring of COPD patients. However, as oxygen therapy
is a prescribed treatment to COPD patients, the monitoring of oximetry and physical activity of
each patient is an asset to a better and more adequate management of COPD and exacerbation
prevention.
3.2.11.2 Propeller sensor
The Propeller sensor [64], which is placed in an inhaler, works by collecting, recording, and ana-
lyzing patient data in real time. It can track how often the patient takes the medication and register
the hour and location of their use. It was also developed to keep track of patients’ symptoms.
This device, which has been approved by the Food and Drug Administration (FDA), is linked via
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Figure 3.6: Autonomous system schematic setup. Adapted from [61].
Bluetooth to a mobile phone. All the recorded data can be shared with the clinicians, allowing
them to remotely monitor the patient’s health and disease progression.
3.2.12 Comparative analysis
To promote an easy comparative analysis between the existing COPD monitoring systems, Table
3.2 summarizes their principal components and characteristics.
Table 3.2: Comparative analysis between the different existing projects on COPD telemonitoring∗.
BWS1 Education Questionnaires Web-Portal Home Monitoring RT Data Analysis2
eCAALYX [54, 55] • • ◦ • • •
CCMC [42] ◦ • • • ◦ ◦
AMICA [56] • • ◦ • ◦ ◦
ASTRI [41] • ◦ ◦ • ◦ ◦
M-COPD [57] ◦ • • • ◦ ◦
CHRONIOUS [58] • ◦ ◦ • • •
VM Health3 [59] • ◦ ◦ • ◦ ◦
EDGE [60] ◦ • • ◦ ◦ ◦
It’s Life! [62] ◦ ◦ ◦ • ◦ •
AERIAL [61] • • • • ◦ •
∗• illustrates the presence of the characteristic and ◦ illustrates the absence of the characteristic.
The market of COPD monitoring systems presents a wide variety of alternatives, as well as
different priorities regarding the implemented features. The presence of a web-portal is the most
common of such features among these systems. The possibility of remote monitoring of the pa-
tient data has been shown to be the most valuable characteristic for most of the systems. Patient
education and biomedical wireless sensors are other features present in a quite significant number
of systems. Since the biggest failures of COPD monitoring lie in education, it is expected that
systems in this area would invest in this feature, as an attempt to surpass these problems. Few sys-
1Biomedical wireless sensors
2Real-Time data Analysis
3VitalmobileTM Health
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tems keep in track the symptoms’ progression, by means of questionnaires, and fewer systems are
capable of giving real-time feedback to the patient. Monitoring the patient’s symptoms is indis-
pensable to achieve a tight control over the disease’s progression and, thus, prevent the occurrence
of severe exacerbations. The monitoring system that will be developed under the scope of this
master’s thesis will take into consideration these valuable characteristics as well as the necessity
of a mobile monitoring system well adapted to the different user’s skills of interaction with this
type of technology. In order to achieve the most complete coverage regarding the prevention of
this pulmonary disease, the focus of the presented system will be more biased towards educational
and symptoms monitoring rather than clinical data monitoring.
Therefore, the next chapter will outline the main functionalities of the proposed system, as
well as detailed analysis of both its architecture and stakeholders.
Chapter 4
COPDHelper
Gathered all the important information about COPD and how viable the usage of telemonitoring
can be to chronic disease patients, the general concept of the monitoring application proposed in
this master’s thesis can be developed, having in mind all the desired characteristics for this kind of
systems. Hereupon, this chapter aims to present the system requirements and its architecture, by
identifying the stakeholders and their interaction with the system, and, also, by systematizing the
technologies and devices needed for this project’s implementation and development.
4.1 General overview
Based on User-Centered Design, the COPDHelper was developed taking into consideration the
needs, wants and limitations of the target user. Thereby, and with this philosophy of product de-
sign, the system will be more adapted to the user, rather than obligating the user to changes in
natural behavior to accommodate the system. Within the context of helping pulmonary diseases’
patients to better self-manage their disease, the COPDHelper encompasses two modules with dif-
ferent purposes:
• The first, named Counseling and Education module, is capable of educating and advising the
user on inhalation and breathing techniques, nutrition and diet tips, and routine exercises.
This module has the purpose of empowering the user to be active in the management of its
chronic disease, so the impact of COPD in the daily activities can be diminished.
• The second, the Monitoring module, allows a periodic monitoring of the user’s oxygen
saturation and the evolution of its symptoms, by means of simple questions and predefined
questionnaires.
In order for this system to be directed to the patient’s needs and disease’s stage, the monitoring
module is adjusted depending on the combined COPD assessment associated to each patient. To
patients with A or C combined COPD assessment, where the level of dyspnea and symptoms is
in the same range (low), the monitoring of oxygen saturation is not needed to keep the disease
under control . It is important to keep an active and healthy lifestyle, exercising everyday and
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keeping healthy nutrition habits. For patients with B or D combined COPD assessments, with high
dyspnea and symptoms levels, it is important not only to keep in track the symptoms progression
and appearance, but also to monitor the oxygen saturation and be sure that its level keeps higher
than 90%.
With this in mind, the monitoring module of COPDHelper is subdivided into two sub-modules:
simple monitoring and complete monitoring. The simple monitoring is intended to monitor only
the evolution of symptoms, by means of a questionnaire. Complete monitoring is intended to not
only monitor the evolution of symptoms, but also to monitor the patient’s vital signs, by means of
biomedical sensors.
As this system will be integrated within the SmartCompanion (Section 3.2.1), some of its
functionalities will also be employed in the development of COPDHelper.
4.2 Requirements analysis
A general overview of the system stakeholders and their role and interaction with the system is a
necessary procedure in order to achieve a global understanding about its main functionalities. In
this section the main features of each tool and resource composing the system will be also outlined.
4.2.1 Tools and Resources
In this section the development platforms used to construct this project are identified, among with
the tools and resources that were necessary to achieve the proposed goals. The SmartCompanion
resources that will be implemented in this system will also be detailed further ahead in this section,
pointing out its main characteristics.
4.2.1.1 Questionnaires
As detailed in Section 2.3, to assess the impact of COPD in the patient’s health status and daily
activities, different kinds of questionnaires were developed. Excluding the ones referred as too
complex and time-consuming in Section 2.3, two valid options could be chosen for the purpose
in the scope of the developed system: CAT (composed by eight questions related to the impact of
COPD and evolution of symptoms) or mMRC (composed by a single question, scaling the feeling
of breathlessness). As the principle of this monitoring system’s questionnaire is to globally assess
the impact of not only dyspnea but every other symptom related to COPD, the CAT questionnaire
was considered to be more adequate and complete than mMRC. For that reason, the CAT was
adapted, in order to be more easily answered on an Android application environment. Instead of
classifying from zero to five (quantitative classification), the answers were converted to a qualita-
tive scale, specific to each question of the questionnaire. In Appendix A, the CAT and mMRC can
be visualized in detail.
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4.2.1.2 Educational Videos
As described in Chapter 2, one of the patient’s main sources of failure in the management of the
disease occurs during the usage the medication inhalers. There are many types of inhalers, each
with different techniques to properly administer the medication. Patient education to properly
intake this medication is, most of the times, miscarried or overlooked. So, for the purpose of
improving the patient’s technique and ensuring that medication is properly inhaled, this system
will integrate educational videos related to each different inhaler in existence. The videos were
made available by the Harvard Vanguard Medical associates, Harvard Medical School - Portugal,
and Deutsche Atemwegsliga.
4.2.1.3 Medication Reminder
One of the SmartCompanion functionalities is the Medication Reminder, an application that, as its
name suggests, creates alarms reminding the user to take the necessary medication. This applica-
tion also informs about the correct dosage of the referred medication, in order to diminish possible
oversights on the part of the user. Hereupon, this functionality will be integrated in COPDHelper.
The frequency of the alarm (daily, weekly, every other day), depends on the registration carried
out by the healthcare specialist, since it is his responsibility to define such parameters.
4.2.2 Stakeholders Identification
Healthcare specialist
The first contact of the COPD patient with the COPDHelper is introduced by the healthcare spe-
cialist. By initializing the patient’s registration on the system and thoroughly explaining what is
the major focus of the system and how the user must and can interact with it, the healthcare special-
ist has a preponderant role in the COPDHelper’s functioning. In order for the monitoring system
to be individually adequate for each patient, during patient’s registration, the specialist introduces
the combined assessment COPD, which will determine the type of monitoring performed, as well
as the corresponding monitoring schedule. It is also his/her responsibility to input information
regarding the prescribed medication, if applicable, as well as the dosage and frequency at which it
should be consumed. By doing so, the system will generate medication reminders at the specified
frequency.
COPD Patient
The final COPDHelper’s users are the COPD patients. Even though the target population is be-
coming generally younger (early 40’s), there is still a considerable incidence of the disease in aged
population, generating, thus, a very heterogeneous array of patients to whom the system shall serve
its purpose. Following this rationale, the system must be designed so it is easy to use even for in-
dividuals with no experience interacting with information technologies, as is the case with the vast
majority of elderly patients. Having identified the main user of the system, it is necessary to also
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define both the tasks and functions which fall under the scope of patient’s direct interaction with
the system.
The COPD patient has an active role in the system by monitoring its vital signs and symptoms
for a better control of its disease. By the means of a biomedical sensor and depending on the spec-
ifications indicated by the doctor upon the patient’s registration, the patient can monitor the vital
signs at home (if (s)he possesses an oximeter) or in the local pharmacy, as well as get counseling
on how to take the prescribed medication, breathing techniques to empower the lung’s function,
and nutrition advice, and exercises to keep an active lifestyle.
Figures 4.1a and 4.1b illustrate the two aforementioned stakeholders and their role in this
monitoring system. Figure 4.1a depicts the complete monitoring sub-module for patients with B
or D combined COPD assessment, whereas Figure 4.1b details the simple monitoring, for patients
with A or C combined COPD assessment. Their role and interaction with the system will be more
detailed in the next sections.
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(a)
(b)
Figure 4.1: Monitoring system use cases: (a) illustrates the use case of the system with the com-
plete monitoring sub-module; and (b) illustrates the monitoring system with the simple monitoring
sub-module implemented
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4.3 Architecture
After a detailed research on the major oversights practiced in the management of COPD, and
the developed alternatives to counteract such practices, the structuring of the developed system’s
architecture was made possible. Envisioning a mobile monitoring system capable of not only pe-
riodically monitor the patient’s vital signs, but also educating and providing counseling on the
different topics that pulmonary rehabilitation programmes cover, the COPDHelper was designed
to be composed by two essential and distinct modules: (1) Counseling and Education and (2)
Monitoring. With the implementation of Medication Reminder, the final system will have three
modules. Since self-awareness of the actual state of the disease is as much important as monitor-
ing of the symptoms and vital signs, the focus of the developed system rests, more precisely, in
detecting and solving the small mistakes on the part of the patient when managing this pulmonary
disease, marking its main difference when compared with available methods (section 3.2).
The overall functioning of the COPDHelper is depicted in Figure 4.2. Starting with patient
registration, upon the first pneumologic consult, where the chronic disease is assessed, the pulmo-
nologist inserts the patient data on the system. This information will determine the specifications
of the COPDHelper, in order for the system to be individually adequated to each patient’s specific
case.
Figure 4.2: System architecture diagram.
The following parameters represent a significant part of the determinant information: Com-
bined COPD assessment, prescribed medication (with or without corticosteroids), and frequency
of medication intake. The first parameter will act as an activator of the type of monitoring: if it ex-
presses A or C evaluation, the simple monitoring sub-module will be activated; on the other hand,
if it expresses B or D, the complete monitoring sub-module will be activated. Regarding the type
of medication and its frequency of usage, these parameters will serve as entries to enable the Med-
ication Reminders. The medication alert will then work autonomously, without any dependency
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on the COPDHelper. Coupled to this alarm is an extra feature, with the goal of reminding the user
to rinse the mouth after the intake of medication, in the case of presence of corticosteroids. By
doing so, the user will prevent a sore throat. After registration is completed, the system is ready to
serve its purpose.
Notwithstanding the fact that the monitoring module is sub-divided, its standard functionalities
allow the patient to:
• check if the oxygen saturation level fits the normal range of acceptability, through oximeter’s
measurements;
• evaluate the impact of the disease in their daily activities, by means of the CAT question-
naire;
• control the progression of the disease, by graphically displaying the evolution of previously
registered results in both questionnaire and oximeter.
The local pharmacy can have an active role in the oxygen saturation monitoring, in case the
user either does not possess an oximeter, or does not have the self-confidence to perform such
measurement without any technical supervision.
Whenever the monitored oxygen saturation value is worrisome, or the impact of COPD in
the user’s daily activities and health status is elevated, the COPDHelper instantly alerts the user,
conceding advices on how (s)he should proceed. These advices go from small physical exercise or
daily living habit tips, if the level of concern is low, to advising medical appointments if the level
of concern is high.
Regardless of how critical the measured parameter values are, COPDHelper is designed so as
to never override medical indications, either by altering medical dosage, counseling the intake of
new medications or suggesting any medical examinations.
The other composing module of this system is, as aforementioned, the counseling and educa-
tion. Unlike the previous module, no feedback is provided to the user. Instead, this module assists
in a more direct way the patient, by clarifying some common doubts and serving as an aid in mul-
tiple daily activities that positively affect the management of the disease. The main functionalities
of this module allow the patients to:
• visualize educational videos on how to properly take the medication with the different exis-
tent inhalers and, so, lessen the mistakes made in taking the prescribed medication;
• do breathing exercises, to learn how to control breathing, diminish the breathlessness sen-
sation, and strength the respiratory muscles;
• perform routine exercises, to keep their life active and provide them an healthier lifestyle;
• consult diet and nutrition tips, to prevent a possible malnutrition, lack of vitamin supple-
ments or mass loss.
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4.4 Stages of Development
The different modules of COPDHelper suffered modulations and adjustments during their devel-
opment, promoted by different factors. In this section the original design of each module will be
presented, as well as the difficulties encountered and their final layout.
• Monitoring module
This module was originally thought to encompass two biomedical sensors, spirometer and
oximeter, with wireless transmission of the collected data to the smartphone. This monitoring
would be autonomous, without requiring the patient to insert any type of data in the system, and
would control not only the vital signs of the patient but also the pulmonary function, one of the
aspects that decays the most with disease progression. These schematics had to be promptly altered
due to the impossibility of acquiring such wireless sensors. However, and despite the fact that the
digital sensor was not acquired, the system is prepared to both easily integrate this sensor as
well as wirelessly register not only patient’s oxygen saturation, but also the blood pressure value.
This feature ceased to be autonomous and started to require the user’s manual introduction of the
oxygen saturation. This data can be obtained with personal oximeters or in the local pharmacies.
The final design of this module can be observed in Figure 4.3.
As previous detailed, after the insertion of the oxygen saturation level, the system will generate
a feedback and present it to the user. If the saturation is below 90%, the system will display a red
light and advise the patient to contact the healthcare specialist (Figure 4.3c). Otherwise (saturation
above 90%), the system will display a green light (Figure 4.3b). In the case of unreasonable levels
of oxygen saturation, COPDHelper alerts the patient to re-introduce values within the acceptable
range (Figure 4.3d).
After the input of this monitored parameter, the patient can save it in the system, for future
consult or analysis on the part of the physician, reintroduce another value in case the previous was
wrongly measured, or simply go back and do not save any record.
Still concerning the monitoring module, on par with the biomedical sensor, was carried out the
implementation of the questionnaire to track the symptoms’ progression. This system’s activity
allows the patient to answer eight question (adapted from the CAT questionnaire) and in the end
of those questions the total impact of COPD disease is determined. Based on the level of impact
(determined using the CAT guidelines detailed on Appendix A.1), the system advises the patient
according to the qualitative classification of impact, ranging from low to very high. The ques-
tionnaire result is saved on a system’s database for further consult and analysis on the part of the
physician, in line with the oxygen saturation. The storage of data allows, in future appointments,
for the doctor to evaluate the physical state of the patient during a specific time period, without
having to rely solely on the information orally transmitted by the patient (possibly altered by mem-
ory limitations or lack of assertivity and objectivity). Figure 4.4 illustrates a demonstration of this
monitoring feature.
• Counseling and Education module
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(a) (b)
(c) (d)
Figure 4.3: Illustrative example of the monitoring module: (a) before the introduction of the pa-
tient’s oxygen saturation (in percentage); (b) and (c) illustrate the generated feedback whenever the
values are within the normal range or below the acceptable, respectively; (d) depicts the generated
alert when the level of oxygen saturation introduced is unreasonable.
As the main goal of this monitoring system is to help improving patient’s self-management of
the disease, the counseling and education module represents a critical part of the system. With this
in mind, this module is composed by four different features (Figure 4.5a). The first, Medication,
encompasses the different educational videos that will help the patient on how to take the medi-
cation correctly, by means of inhalers (Figures 4.5b and 4.5c). All videos are available to every
patient, covering the possible changes of inhalers during the treatment and management of this
disease.
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(a) (b) (c) (d)
Figure 4.4: Illustrative example of questionnaire: (a) shows a simple introduction to the patient
about the purpose of this questionnaire; (b) illustrates a question example; (c) and (d) depicts the
result of the questionnaire and the impact’s classification in two of the four possible classifications
The Respiration feature is destined to guide the patient on respiratory exercises, to help learn
how to control the respiration and strengthen the respiratory muscles. As the green circle expands
and contracts (illustrated in Figure 4.6b), the patient must inhale or exhale respectively, fulfilling
the whole duration of each instance. This exercise duration must be close to 5 minutes and repeated
3 times a day. The Exercises feature, on the other hand, will encompass the most diverse exercises
to keep the patient active, in order to contrary the sedentary lifestyle characteristic of patients
suffering from lung diseases. Unfortunately, at this process’s stage, this feature is still under
development, as requires the integration of the ExerGames, another Franhofer’s application. The
Nutrition functionality advises the patient on how to keep an healthy diet, giving key information
about the different food portions composing the food balance wheel, and how the ingestion of
such portions positively or negatively affects the pulmonary functions and disease (Figures 4.6c
and 4.6d). By clicking on the different available images, the user can learn relevant nutrition’s
guidelines in order to prevent a possible mass loss, lack of vitamin supplements or malnutrition,
common on COPD patients that do not take special attention in their food habits.
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(a) (b)
(c)
Figure 4.5: Illustrative example of (a) this module layout and (b, c) medication’s education videos.
(b) shows the list of the different inhalers and (c) an example of an educational video layout.
(a) (b) (c) (d)
Figure 4.6: Illustrative examples of the features Respiration and Nutrition. (a) and (b) show the
input of the respiratory exercise and the exercise itself; (c) and (d) show advices for diet and
nutrition respectively.
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4.5 Final Monitoring System
Gathered all the different modules’ attributes, the final aspect of the designed monitoring system
is as illustrated in the set of subfigures displayed in Figure 4.7. For demonstration purposes, the
COPDHelper is set to a patient with combined COPD assessment of B, in order to activate all the
system’s functionalities.
(a) (b)
Figure 4.7: The COPDHelper: (a) shows the representative icon adapted to the SmartCompanion
layout; (b) illustrates the main menu of the system, with all of its attributes active.
The chosen icon for COPDHelper followed the directives of SmartCompanion applications,
which determine that icons for applications in the Care group should present red color. This
facilitates the senior user in the identification of the application’s scope (Figure 4.7a).
As mentioned in Section 4.3, the information entered in the system by the healthcare profes-
sional will serve as entries to the Medication Reminder application. For demonstration purposes,
one situation where the patient was taking Symbicort with the presence of corticosteroids was
simulated. The corresponding result is depicted in Figure 4.8.
In summary, a mobile monitoring system capable of not only monitoring but also advising and
educating the patients in the more diverse aspects of the disease was successfully developed. How-
ever, future improvements and features can be equated and will be mentioned in further detail in
the next chapter. Furthermore, an evaluation regarding the COPDHelper usability was performed
and will also be further detailed in the following chapter.
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(a) (b)
Figure 4.8: Illustrative example of the medication reminder: (a) shows the alarm to remind the
patient to take the medication and (b) alerts the patient to rinse the mouth with water in case of
medication intake with corticosteroids.

Chapter 5
Evaluation Results and Discussion
When developing a product, or, more precisely in this case, an application based on a user-centered
design, the user experience is one of the most important aspects to have in mind when managing
and developing the proposed system. User Experience (UX) focuses on having a deep understand-
ing of users, what they need, what they value, their abilities and limitations. Within the various
factors that influence the UX are system usability, directed to how well users can learn and use a
product to achieve their goals, and also how satisfied they are with that process [65]. With this in
mind, the following chapter will present the methodology and the results obtained regarding the
system usability evaluation, as well as a detailed discussion focused on the developed system, its
values and limitations.
5.1 System Evaluation
Jakob Nielsen [66] reports that the most basic and useful method for studying usability is user
testing, which has three components: (1) gather some representative users, (2) ask the users to
perform representative tasks with the application/product and (3) observe that interaction and col-
lect where they succeed, and where they had difficulties and doubts. It is important that during user
testing, no interactions happen between the developer and user. By considering the user’s profile,
the context, the needs, and the interaction with the system, and using those parameters in favor
of the system’s development, the final user’s interaction will be more fit to the purpose as well
as more intuitive, reducing the need for training and support, error rates, increasing satisfaction
and productivity, and diminishing a possible loss of interest on using such system. All of these
aspects are important for telemonitoring systems, intended as a solution to be adopted at scale
for the management of patient suffering from long-term conditions in an ageing population [67].
However, as usability does not exist in any absolute sense, there is no objective way of measuring
it. If the usability of a system is defined by the context in which that system is used, the specific
measurements should also be defined by that same context. A possible way to make more gener-
alised assessments of usability is through the use of questionnaires [68]. Hereupon, the usability
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evaluation of the COPDHelper will be based on a standardized questionnaire and will be detailed
in the next section.
5.1.1 Methodology
To evaluate COPDHelper in terms of usability, it was proposed to 13 volunteers, with ages between
29 and 70 years, in different stages of COPD, to interact with the system by performing different
tasks. Afterwards, the filling of a questionnaire allowed the users to evaluate their interaction with
COPDHelper. This questionnaire is available in Appendix B.1. It is worth mentioning that the
constitution of this group was made to encompass patients from different age ranges, in order to
not only evaluate the system usability in daily users of smartphones, but also on patients without
a daily contact with these type of technologies.
With the purpose of better simulating the real environment where this application will be in-
serted, the usability tests were conducted by a healthcare specialist, previously acquainted with the
context and system’s functionalities. Therefore, such tests were performed in a hospital environ-
ment, at the endpoint of each pneumologic consult, under supervision of the system’s developer.
Hereupon, and before starting the test and evaluation, a simple presentation was made to each
user, explaining the major objective and functionalities of the developed application. Completed
the contextualization, it was asked each user to execute some tasks, related to the daily activities
of a COPD patient in the management of the disease:
• Assess the level of oxygen saturation and introduce the respective value on the system;
• Assess the impact of the pulmonary disease in the previous week, by filling the questionnaire
component;
• Visualize the educational video referred to the inhaler in use.
Completed the tasks, the user was able to freely explore the application, in order to acquire a
more global view of the system. Afterwards, the user was asked to fill the usability questionnaire,
having in consideration the experience acquired during the interaction and task’s execution,. The
referred questionnaire was composed by twelve questions, being that the ten first were related to
the already existing System Usability Scale (SUS). SUS is a likert scale, developed in 1986, that
has become an industry standard with references over 600 publications, by evaluating a variety of
aspects of system usability, such as the need for support, training, and complexity of a hardware,
software, system or product [68]. As SUS globally assesses such usability, the incorporation of two
more questions, more directed to the senior sector and their ability to interact with such system,
was seen as necessary. As a complement to this questionnaire, the user also had the opportunity to
suggest possible changes in the system’s design or new features they found to play a relevant part
in future versions of to the project.
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5.1.2 Results
The questionnaire results were processed in order to express them in the standardized way. With
this usability scale, an overall score above 68 is considered above average and an overall score
under 68 is considered below average. As SUS is a 10 item questionnaire with 5 response options,
the contribution of each item is summed to achieve the overall score. However, this summation is
constrained by the following parameters [68]:
• For odd items: subtract one from the user response;
• For even-numbered items: subtract the user responses from 5;
• Add up the converted responses for each user and multiply that total by 2.5.
The average score of SUS observed for the developed system was 81.3± 12.6 out of 100. Is
important to mention that this result is not a percentage, as the middle point of this scale is 68
(from 0 to 100) [68]. Nevertheless, and with this in mind, COPDHelper proved to have a good
learnability and usability dimension in a very heterogeneous group of volunteers, both in terms of
age and smartphone usage experience. With this in mind, Figure 5.1 shows the average result for
each of the ten items, in order to allow an independent and clear analysis in the different aspects
assessed by the questionnaire. The items 4 and 10 evaluate the learnability dimension and the
other 8 items the usability dimension. As referred above, the last 2 questions of the questionnaire,
which were designed outside the scope of the SUS items, were introduced so that users could rate
the usability of the system by senior users, and are also displayed in Figure 5.1, making a total of
12 items evaluated from 0 to 4 (being 4 the most positive classification).
Figure 5.1: Usability test results. Each dot represents the average score of each questionnaire’s
item.
Analysing, primarily from a global point of view, the results depicted in Figure 5.1, there are
two items that stand out from the rest. Item 4, related to learnability, stands out negatively and item
6, related to a possible existence of inconsistencies in the system, stands out positively. Overall,
the usability of this system was classified as good (equals to a 3 in the scale). All the volunteers
had the opinion that the system did not have any inconsistencies, was easy to use and its diverse
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functions were well integrated. Notwithstanding this general assessment, as the group’s age and
experience range were highly heterogeneous, some of the items did not gathered a consensual
assessment, especially when questioned about the capability of users to interact with the system
without any technical help and about the capability of most people to rapidly learn how to interact
with and use the system. The mobile nature of the application, using a touch-screen cellphone,
aroused doubts to all of the participants about the ability of COPD patients to use this monitoring
system, in particular elder patients. However, when questioned about if the system could help
senior patients to learn and control their disease, the result was, in general, positive (Item 12).
Globally, this results support the pre-defined idea of being a challenge to adapt this system so
that users with little or no contact with with type of technology can make the most out of all its
features. On Appendix B are available the questionnaire and information on test data.
As a way of also gathering healthcare specialists’ feedback about the utility of such systems,
and collecting possible relevant suggestions, three healthcare specialist were interviewed (pneu-
mologist, immunoallergologist and general practitioner). Their general opinion regarding the ap-
plicability of COPDHelper in the pretended context was consensually good. As concluded from
the questionnaire’s results, the specialists alerted for a possible incapacity on the part of certain
patients to use this system and making the most out of it, suggesting as a possible improvement
the introduction of a brief tutorial, as a way to inform and teach the user how to interact with
each section. Concerning the questionnaire’s feature, it was also suggested the introduction of a
"observations and comments" block, in order to allow the input of relevant extra aspects about the
expectoration (consistency and color, for example).
Although this results show some promise, the COPDHelper is still far away from perfection
and in the next sections some of its main limitations will be pointed out.
5.2 General Discussion
COPDHelper, like most systems in the first stages of their development, possesses a number of
flaws and limitations that must also be highlighted in order to provide a solid base for future
improvements. Starting with the monitoring module, where the value of oxygen saturation is as-
sessed, one of the main limitations regards the need for a manual input of such data. As was
previously referred, initially the main goal of the monitoring module was to automatically acquire
the oxygen saturation signal, making use of a wireless digital oximeter. Unfortunately, the ac-
quisition of such sensor was rendered impossible by the lack of local distribution of the desired
sensor or identical models in Portugal and other European countries. With an estimated deadline
for this project’s development, the most viable solution found to bypass this obstacle was enabling
the manual insertion of the oxygen saturation level, making use of a simple oximeter, both easily
accessible (at local pharmacies, for example) and affordable to the average user.
Still regarding the monitoring features, it was originally thought to also integrate a wireless
digital spirometer, to serve as a complement to the oxygen saturation assessment. But, similarly to
what happened with the digital oximeter, the acquisition of such spirometer was made impossible,
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not only due to problems with local distributors, but also because its high acquisition price, which
far exceeded what was supported by this project’s budget.
Now concerning the counseling and education module, the main present limitations befall in
the medication and respiration components. Not all of the educational videos available at this
stage of development are presented in european portuguese. The scarcity of portuguese-spoken
educational videos led to the integration of spoken videos in both english and brazilian portuguese.
As for the respiration component, the absence of an audio support to the circle animation (which
guides the user in the respiratory exercise) is a limitation. The integration of such aspect would
make this feature more easy to comprehend and more intuitive. One of the problems encountered
when trying to implement such parameter was the lack of RAM memory available to run at the
same time the animation and voice support.

Chapter 6
Conclusions and Future Work
Chronic obstructive pulmonary disease is a serious health problem which places a significant eco-
nomic burden on health systems worldwide, due mostly to a significant number of acute exacerba-
tion events. It is estimated that its global burden will increase substantially in the coming decades,
in a directly proportional relation with the noticeable rise in smoking habits. The prevention of the
acute exacerbations is a common goal of COPD treatment, being imperative a patient education
and self-management programs to arouse patient’s awareness of their activity behavior and health
condition, and also to educate them how to proper take the prescribed medication.
Home telemonitoring is defined as the use of telecommunication technologies to transmit data
on patient’s health status from home to a healthcare center. Based on literature review, home
telemonitoring of COPD seems to be a promising patient management approach that produces
accurate and reliable data, empowers patients, as well as their activity behavior and potentially
improves their health-related quality of life. It is also increasingly seen as a way to bridge the gap
between professional care and patient self-management.
As the main objective of the proposed master’s thesis was the development of a mobile appli-
cation that, with the principles of telemedicine and telemonitoring, could diminish this gap and had
the capability of assisting and guiding COPD patients towards a improved self-management of the
disease, the overall balance is positive, with the main goals of the proposed project successfully
fulfilled.
The result of such work is incorporated in the COPDHelper, an application capable of guid-
ing the user in the diverse fields of pulmonary rehabilitation and management of diseases such as
COPD. Making use of external biomedical sensor and questionnaires, the vital signs and symp-
toms’ progression are periodically assessed, to diminish the number of acute exacerbations pro-
voked by oversights and lack of self-awareness of the symptom’s progression.
In comparison with the already available systems or studies described in the Chapter 3, COPDHelper
is a strong competitor in the sector of symptom’s progression assessment and real-time feedback,
as only 4 of the 10 referred systems are capable of analysing the collected data and instantly gener-
ate a feedback, and only 1 of those systems tracks the symptom’s manifestation. Also, the capacity
of the COPDHelper to remind the patient about the need to take the medication, while also guid-
47
48 Conclusions and Future Work
ing them in how to properly take it, is another strong argument when comparing with the state
of the art in telemonitoring systems. Although most of the referred systems have a mobile com-
ponent that allows a continuous monitoring of the patient’s activities, the fact that COPDHelper
is integrated within the SmartCompanion, which supports other valuable monitoring features and
applications, enhances the monitoring potential and versatility of this system.
The COPDhelper usability among COPD patients was tested and confirmed by the use of
a questionnaire. A positive usability evaluation renders the system’s acceptability easier, as it
improves and facilitates the interaction between the user and the system, thus reducing the natural
lack of interest that is associated to highly complex and non-intuitive software.
Nevertheless, there are still some features that need further improvements before the applica-
tion is fit for routine use.
6.1 Future Work
With the aforementioned COPDHelper limitations in mind, a set of future improvements can be
outlined. As mentioned during the writing of this thesis, some features of COPDHelper were
not implemented, but both the system and, ultimately, the final user would benefit with their in-
tegration. Starting with one of the counseling and education module’s components, exercises,
the implementation of ExerGames, another SmartCompanion application, composed by different
exercises and games, would complete this module, by making the user more active and, thus, im-
proving his quality of life and and control over the disease. Also in this module, an uniformization
of the educational videos and its spoken-language would be necessary, especially considering that
not all the potential users will dominate more than their native language. Also, and as previously
referred, the addition of an audio support to the respiratory exercises will further increase the user
experience and make it more intuitive.
Regarding future prospectives to the monitoring module, the utilization of wireless sensors
could be seen as an advantage, especially to elderly patients, since the manual introduction of
the assessed values would be rendered obsolete, representing one less level of dependency of the
system on the user.
Another feature that was initially thought of to be part of the COPDHelper was Mover, an-
other application of the Fraunhofer’s Swiss Army Knife, that by making use of the smartphone’s
accelerometers and gyroscope, can determine if the user is being active or not. The implemen-
tation of the Mover’s library would be beneficial to, upon a long inactivity detection (excluding
the hours for nightly rest), alert the user and recommend specific exercises to fight the sedentary
lifestyle common in COPD patients at advanced stages, mostly due to progressive deterioration of
the respiratory capacities.
Also as future work is the implementation of a functionality capable of adapting the main
features of the software to fit each specific patient’s diagnosis and observations, performed a priori
by the healthcare specialist. By accessing previous diagnosis, stored in an Internet server instead
of being input into the mobile application by the healthcare specialist, such information would
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be used to make the application unique and adapted to each patient’s needs. In this way, upon
patient’s registration in the mobile application, this system would connect to the Internet server
and acquire the respective medical information.
It is also noteworthy, and having in consideration the results of the usability tests, that a design
improvement destined to make the application more adapted and easy understandable to elderly
people would be a valuable asset to improve both the acceptance and system’s functionality.
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Appendix A
Questionnaires
A.1 COPD Assessment Test
USERGUIDE 11
In addition, for each scenario, the CAT Development 
Steering Group has proposed some potential management 
considerations:11
CAT 
score
Impact 
level
Broad clinical picture of the 
impact of COPD by CAT score 
Possible management considerations
>30 Very high Their condition stops them doing everything they 
want to do and they never have any good days. If 
they can manage to take a bath or shower, it takes 
them a long time. They cannot go out of the house 
for shopping or recreation, or do their housework. 
Often, they cannot go far from their bed or chair. 
They feel as if they have become an invalid.
Patient has signifi cant room for improvement 
In addition to the guidance for patients with low and medium impact 
CAT scores consider:
• Referral to specialist care (if you are a primary care physician)
Also consider:
• Additional pharmacological treatments
• Referral for pulmonary rehabilitation
• Ensuring best approaches to minimising and managing exacerbations
>20 High COPD stops them doing most things that they want 
to do. They are breathless walking around the home 
and when getting washed or dressed. They may be 
breathless when they talk. Their cough makes them 
tired and their chest symptoms disturb their sleep 
on most nights. They feel that exercise is not safe 
for them and everything they do seems too much 
effort. They are afraid and panic and do not feel in 
control of their chest problem.
10-20  Medium COPD is one of the most important problems that 
they have. They have a few good days a week, but 
cough up sputum on most days and have one or 
two exacerbations a year. They are breathless on 
most days and usually wake up with chest tightness 
or wheeze. They get breathless on bending over and 
can only walk up a fl ight of stairs slowly. They either 
do their housework slowly or have to stop for rests.
Patient has room for improvement – optimise management
In addition to the guidance provided for patients with low impact CAT scores 
consider:
• Reviewing maintenance therapy – is it optimal?
• Referral for pulmonary rehabilitation
• Ensuring best approaches to minimising and managing exacerbations
• Reviewing aggravating factors – is the patient still smoking?
<10 Low Most days are good, but COPD causes a few 
problems and stops people doing one or two things 
that they would like to do. They usually cough 
several days a week and get breathless when playing 
sports and games and when carrying heavy loads. 
They have to slow down or stop when walking up 
hills or if they hurry when walking on level ground. 
They get exhausted easily.
• Smoking cessation
• Annual infl uenza vaccination
• Reduce exposure to exacerbation risk factors 
• Therapy as warranted by further clinical assessment.
5 Upper limit of normal in healthy non-smokers
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MODIFIED MEDICAL RESEARCH COUNCIL 
DYSPNEA SCALE 
 
ID NUMBER:         FORM CODE:   MRC VERSION: 1.0  10/26/10 
Visit 
Number     SEQ #  
  
 
 
 
 
0a) Form Date ........... / /  0b) Initials ...........  
 
 
 
  
 
Please choose the one best response to describe your shortness of breath. 
 
Grade 
 
0 “I only get breathless with strenuous exercise” 
 
 
1 “I get short of breath when hurrying on the level or walking up a slight hill” 
 
 
2 “I walk slower than people of the same age on the level because of breathlessness or have to 
stop for breath when walking at my own pace on the level” 
 
 
3 “I stop for breath after walking about 100 yards or after a few minutes on the level” 
 
 
4 “I am too breathless to leave the house” or “I am breathless when dressing” 
 
 
 
 1. Grade ......................................................  
 
 
 
Instructions:  This form should be completed during the participant’s visit. Choose the one best 
response. 
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Appendix B
Usability Evaluation
B.1 Usability Questionnaire
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Profissão:
idade: M □  F □
Usando a escala abaixo, por favor coloque um círculo no número mais próximo da palavra que mais
se aproxima aos seus sentimentos acerca do COPDHelper.
1. Penso que gostaria de usar este sistema frequentemente
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
2.  Achei o sistema desnecessariamente complexo
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
 
3. Achei o sistema fácil de usar
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
4. Penso que precisaria do apoio técnico para conseguir usar o sistema
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
5. Achei que as várias funções do sistema estavam bem integradas
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
6. Achei que havia demasiadas inconsistências neste sistema
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
7. Imagino que a maioria das pessoas consegue aprender a usar este sistema muito rapidamente
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
8. Achei o sistema muito incómodo de usar
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
9. Senti-me muito confiante ao usar o sistema
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
10. Precisei de aprender muitas coisas antes de conseguir começar a usar o sistema
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
Responda às duas últimas questões considerando uma mudança de perspectiva mais focada na 
população envelhecida
11.  Utilizadores séniores seriam capazes de utilizar o sistema
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
 
12.  Este sistema ajudaria os pacientes séniores a entender e controlar a sua doença
Discordo
fortemente 1 2 3 4 5
Concordo
fortemente
 
Sugestões:
1. Mudaria algum aspecto do COPDHelper?
2. Adicionaria alguma funcionalidade extra ao presente sistema?
3. Outras observações:
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B.2 Questionnaire Results
Table B.1: Average scores and standard deviations of each usability questionnaire’s item
Item 1 2 3 4 5 6 7 8 9 10 11 12
Mean 3 3 3 3 3 4 3 3 3 3 2 3
Standard Deviation 0.8 0.6 0.8 1 0.5 0.5 1 0.8 0.8 1 1 0.8
